Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress - Induced recurrent thrombosis in the injured carotid artery of the rabbit

Circulation Research

Volumn 84, Issue 12, 1999, Pages 1446-1452

  Nishida, Takahiro ^a   Ueno, Hikaru ^a,d   Atsuchi, Nobuhiko ^a   Kawano, Ryuji ^a   Asada, Yujiro ^b   Nakahara, Yo ^c   Kamikubo, Yu Ichi ^c   Takeshita, Akira ^a   Yasui, Hisataka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Kaketsuken   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; Blood flow; Gene transfer; Inhibitor; Thrombosis

Indexed keywords

ADRENALIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BLOOD FLOW VELOCITY; CAROTID ARTERY THROMBOSIS; COMPLEX FORMATION; GENE TRANSFER; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; RABBIT; RECURRENT DISEASE; SHEAR STRESS; THROMBOCYTE AGGREGATION;

EID: 0033603552     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.12.1446     Document Type: Article

References (40)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med. 1992;326:242-250.
2. Williams DO, Braunwald E, Thompson B, Sharaf BL, Buller CE, Knatterud GL. Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction: observations from the TIMI IIIB Trial. Circulation. 1996;94:2749-2755.
3. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention: EPIC Investigators. Circulation. 1995;91:2882-2890.
4. Adgey AA. Bleeding complications with new antithrombotics used in ischaemic heart disease. Haemostasis. 1996;26:237-246.
5. Folts JD, Rowe GG, Rao GHR. Problem with aspirin as antithrombotic agent in coronary artery disease. Lancet. 1988;1:937-938.
6. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 1997;78:200-204.
7. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 1995;46:103-112.
8. Lindahl AK. Tissue factor pathway inhibitor from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res. 1997;33: 286-291.
9. Schneider MD, French BA. The advent of adenovirus: gene therapy for cardiovascular disease. Circulation. 1993;88:1937-1942.
10. Nabel EG. Gene therapy for cardiovascular disease. Circulation. 1995; 91:541-548.
11. Baek S, March KL. Gene therapy for restenosis. Circ Res. 1998;82: 295-305.
12. Ueno H, Li JJ, Tomita H, Yamamoto H, Pan Y, Kanegae Y, Saito I, Takeshita A. Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. Arterioscler Thromb Vasc Biol. 1995;15:2246-2253.
13. Ueno H, Yamamoto H, Ito S, Li JJ, Takeshita A. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol. 1997;17: 898-904.
14. Ueno H, Haruno A, Morisaki N, Furuya M, Kangawa K, Takeshita A, Saito Y. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/ paracrine loop. Circulation. 1997;96:2272-2279.
15. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108: 193-199.
16. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A. 1996;93: 1320-1324.
17. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiki H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakao T, Kumeda K, Kato H. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol. 1997;55:183-187.
18. Kamikubo Y, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 1997;407:116-120.
19. Kamei S, Kamikubo Y, Hamuro T, Fujimoto H, Ishihara M, Yonemura H, Miyamoto S, Funatsu A, Enjyoji K, Abumiya T. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem. 1994;115:708-714.
20. Sandset PM. Chromogenic substrate assay of extrinsic pathway inhibitor: levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 1991;2:425-433.
21. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry. 1995;34:5725-5735.
22. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
23. Channon KM, Qian H, Youngblood SA, Olmez E, Shetty GA, Neplioueva V, Blazing MA, George SE. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries. Circ Res. 1998;82:1253-1262.
24. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83(suppl): IV3-IV14. Review.
25. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry. 1991;30:10371-10376.
26. Strony J, Beaudoin A, Brands D, Adelman B. Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol. 1993;265:H1787-H1796.
27. Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 1976;54: 365-370.
28. Wilcox JN, Smith KM, Schwartz S, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86:2839-2843.
29. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest. 1993;91:2253-2259.
30. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Semen GGN. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost. 1998;79:495-499.
31. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res. 1994;74:56-63.
32. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 1995;92: 3041-3050.
33. Anderson HV, Kirkeeide RL, Krishnaswami A, Weigelt LA, Revena M, Weisman HF, Willerson JT. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol. 1994;23:1031-1037.
34. Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation. 1982;65:248-255.
35. 2+ mobilization and protein kinase C activation. J Clin Invest. 1993;91:547-552.
36. Willerson JT, Yao GK, McNatt J, Benedict CR, Anderson HV, Golino P, Murphree SS, Buja LM. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci U S A. 1991;88:10624-10628.
37. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis. 1997;133:213-219.
38. Brown DM, Kania NM, Choi ET, Lantieri LA, Pasia EN, Wun T-C, Khouri RK. Local irrigation with tissue factor pathway inhibitor inhibits intimal hyperplasia induced by arterial interventions. Arch Surg. 1996; 131:1086-1090.
39. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nature Med. 1996;2:293-298.
40. Zoldhelyi P, McNatt J, Xu XM, Loose-Mitchell D, Meidell RS, Clubb FJ Jr, Buja LM, Willerson JT, Wu KK. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 1996; 93:10-17.